Repligen (1RGEN) Stock Overview
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
1RGEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeRepligen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$103.80 |
| 52 Week High | US$139.35 |
| 52 Week Low | US$99.56 |
| Beta | 1.09 |
| 1 Month Change | 6.07% |
| 3 Month Change | -10.86% |
| 1 Year Change | -10.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RGEN | IT Life Sciences | IT Market | |
|---|---|---|---|
| 7D | 2.4% | 2.4% | 1.6% |
| 1Y | -10.7% | -12.7% | 20.1% |
Return vs Industry: 1RGEN exceeded the Italian Life Sciences industry which returned -12.7% over the past year.
Return vs Market: 1RGEN underperformed the Italian Market which returned 20.1% over the past year.
Price Volatility
| 1RGEN volatility | |
|---|---|
| 1RGEN Average Weekly Movement | 11.1% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.2% |
| 10% least volatile stocks in IT Market | 3.1% |
Stable Share Price: 1RGEN's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1RGEN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,000 | Olivier Loeillot | www.repligen.com |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Repligen Corporation Fundamentals Summary
| 1RGEN fundamental statistics | |
|---|---|
| Market cap | €5.93b |
| Earnings (TTM) | €43.73m |
| Revenue (TTM) | €649.53m |
Is 1RGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RGEN income statement (TTM) | |
|---|---|
| Revenue | US$763.34m |
| Cost of Revenue | US$357.71m |
| Gross Profit | US$405.63m |
| Other Expenses | US$354.23m |
| Earnings | US$51.40m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 53.14% |
| Net Profit Margin | 6.73% |
| Debt/Equity Ratio | 26.0% |
How did 1RGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 20:17 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Repligen Corporation is covered by 29 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas |